Schulman IRB’s IBC Service to Launch in May
Cincinnati, OH and Durham, NC – Schulman IRB announced today that its commercial institutional biosafety committee (IBC) service will launch in May 2017. The IBC service represents Schulman’s response to requests from research sponsors, CROs and institutions seeking an independent option for establishing IBCs when required by federal guidelines.
Led by Dr. Daniel Eisenman, Ph.D., RBP, SM(NRCM), CBSP, the IBC service provides comprehensive support for research sponsors and sites conducting research involving recombinant DNA (genetic engineering). Schulman’s commercial IBC service will support clinical, pre-clinical and non-clinical research, providing all components to complement an existing IBC or build and administer an entirely new IBC.
“Clinical trials involving recombinant DNA are becoming more common, especially in oncology,” said Michael Woods, President and CEO of Schulman IRB. “The IBC service will compliment and coordinate with Schulman’s existing IRB services, providing the expertise and efficiencies necessary to help clients conduct this research safely and expediently.”
NIH Guidelines require both IRB and IBC review for gene therapy (human gene transfer) research that receives NIH funding or takes place at NIH funded sites. The IBC reviews safety aspects of research involving recombinant DNA (genetic engineering), including risks associated with genetic modifications and experimental procedures as well as occupational and environmental safety.
About Schulman IRB
Schulman IRB has been a leader in the protection of human research participants in the U.S., Puerto Rico and Canada since 1983. Schulman offers thorough, timely IRB review services – including dedicated review capabilities for all phases of research across all therapeutic areas – to clinical trial sponsors, CROs, investigators and institutions. Schulman also provides global consulting services in clinical quality assurance (CQA) and human research protections (HRP), and its commercial institutional biosafety committee (IBC) service will launch in May 2017. Fully accredited by the Association for the Accreditation of Human Research Protection Programs (AAHRPP), Schulman has an unparalleled clean audit history with the Food and Drug Administration (FDA).
For more information, please visit http://www.sairb.com or follow @SchulmanIRB on Twitter or on LinkedIn.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
